BMS 754807

Drug Profile

BMS 754807

Alternative Names: BMS-754807

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Pyrazoles; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 01 Nov 2014 Bristol-Myers Squibb completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Canada and Puerto Rico (NCT01225172)
  • 17 Jun 2013 Bristol-Myers Squibb terminates in its phase I/II trial for Solid tumours (combination therapy) in USA & Canada (NCT00908024)
  • 30 Apr 2013 Bristol-Myers Squibb completes a phase I trial in Solid tumours (monotherapy) in Australia (NCT00569036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top